Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of netupitant + palonosetron versus aprepitant + palonosetron for prevention of chemotherapy-induced nausea and vomiting across repeated chemotherapy cycles
2010-023297-39Phase 3Completed
- Sponsor
- Helsinn
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Netupitant + palonosetron fixed-dose combination with Active control: aprepitant + palonosetron (2 arms). Primary endpoints: Complete response during delayed phase, Complete response during acute phase and 5 more. Started Apr 2011; status: completed.
02
Drugs
netupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2010-023297-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023297-39.